Patient’s Choice Laboratories™ (PCL) is proud to offer the following Pharmacogenetic testing panels to help you to better serve your patients. Pharmacogenetic testing provided by PCL will allow you to deliver personalized medicine to your patients that is custom-tailored to their specific needs and conditions such as pain management, mental health, and cardiovascular risk. These tests have been extensively validated in-house by highly trained scientists under strict conditions that satisfy CLIA and CAP requirements.
Testing genes involved in metabolism of pharmaceuticals can provide important genetic information to help you identify the ideal drug for your patients, offering the opportunity to maximize the therapeutic effect while reducing adverse drug reactions (ADRs).
Results will be reported in standard nomenclature such as “Poor Metabolizer”, “Intermediate Metabolizer”, “Normal Metabolizer”, and “Rapid Metabolizer”, with specific recommendations based on clinical research for the medications your patients are taking that can be listed on the requisition form.
Poor Metabolizer (PM): Presence of mutations, usually on both chromosomes or in multiple locations on the gene, which significantly decrease or completely inhibit expression of the mutated gene. This generally results in a decreased dosage recommendation or change in medication to something more easily metabolized by the patient.
Intermediate Metabolizer (IM): Presence of mutations on only one chromosome, or multiple mutations only partially effecting expression of the mutated gene.
Rapid Metabolizer (RM): Presence of mutations, usually on both chromosomes or in multiple locations on a gene, which significantly increase expression of the mutated gene. This generally results in an increased dosage recommendation.
Normal Metabolizer (NM): No detected mutations (wild type).
A Novel Collection Kit for Genetic Testing:
Click to open a full explanation of Patient Choice Laboratories’ COPAN eNAT with FLOQSwabs Testing
References: Blood Transfus. 2011 Apr; 9(2): 120–138. | Hum Genet.2001 Oct;109(4):369-84. | Trends Pharmacol Sci.2004 Apr;25(4):193-200. | Clin Biochem Rev. 2006 Feb;27(1): 17–25. | Clin Chem. 1997 Sept;43(9):1678-1683 | 2003;107: I-9-I-16. | Am Fam Physician.2007 Aug;76(3):391-396. | Pharmacogenet Genomics. 2009 Jul;19(7):556-8.